Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort

Drug development for advanced AD therapies required a real-world baseline understanding of which patient characteristics—clinical, demographic, and insurance-related—predicted advanced systemic therapy initiation versus remaining on conventional treatments, to inform trial enrollment design and commercial access strategy.

The TARGET-DERM AD cohort was analyzed to describe baseline characteristics and identify independent predictors of advanced systemic therapy initiation using multivariable logistic regression, providing the first large-scale real-world characterization of the AD treatment decision landscape in the US.

Establishing that disease severity, insurance type, and site of care independently predict AST initiation identifies actionable access barriers and informs trial site selection, enrollment enrichment, and health equity strategies for AD drug development programs.

Real-world AST initiation predictor analysis for AD trial enrollment and access strategy design, Baseline AD population characterization for drug development representativeness assessment, Treatment decision driver identification supporting payer access and commercial strategy for AD biologics